Cutting Edge: Defective NK Cell Activation in X-Linked Lymphoproliferative Disease
- 1 October 2000
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 165 (7) , 3549-3553
- https://doi.org/10.4049/jimmunol.165.7.3549
Abstract
X-linked lymphoproliferative disease (XLP) is characterized by a selective immune deficiency to EBV. The molecular basis of XLP has been attributed to mutations of signaling lymphocytic activation molecule-associated protein, an intracellular molecule known to associate with the lymphocyte-activating surface receptors SLAM and 2B4. We have identified a single nucleotide mutation in SLAM-associated protein that affects the NK cell function of males carrying the mutated gene. In contrast to normal controls, both NK and lymphokine-activated killer cell cytotoxicity was significantly reduced in two XLP patients. In addition to decreased baseline cytotoxicity, ligation of 2B4 significantly augmented NK lytic function in normal controls but failed to enhance the cytotoxicity of NK cells from XLP patients. These findings suggest that association of SAP with 2B4 is necessary for optimal NK/lymphokine-activated killer cytotoxicity and imply that alterations in SAP/2B4 signaling contribute to the immune dysfunction observed in XLP.Keywords
This publication has 32 references indexed in Scilit:
- Novel mode of ligand binding by the SH2 domain of the human XLP disease gene product SAP/SH2D1ACurrent Biology, 1999
- Activated T cells and cytokine-induced CD3 + CD56 + killer cellsAnnals of Hematology, 1997
- Large clonal expansions of CD8+ T cells in acute infectious mononucleosisNature Medicine, 1996
- X-Linked Lymphoproliferative Disease: Twenty-Five Years after the DiscoveryPediatric Research, 1995
- Function of CD48 and its regulation by Epstein-Barr virusBiochemical Society Transactions, 1993
- Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes.The Journal of Experimental Medicine, 1993
- Defective natural killing activity but retention of lymphocyte-mediated antibody-dependent cellular cytotoxicity in patients with the X-linked lymphoproliferative syndromeCellular Immunology, 1986
- Cell‐mediated immunity to Epstein‐Barr virus (EBV) and natural killer (NK)‐cell activity in the X‐linked lymphoproliferative syndromeInternational Journal of Cancer, 1982
- Deficient Natural Killer Cell Activity in X-Linked Lymphoproliferative SyndromeScience, 1980
- X-LINKED RECESSIVE PROGRESSIVE COMBINED VARIABLE IMMUNODEFICIENCY (DUNCAN'S DISEASE)The Lancet, 1975